Great madamswer,
....and in the process of discussion, it's easy to see where there is skewed analysis.
All you do is talk about income. You don't give any kind of value to the technology being proven so far in clinical trials, nor of the advanced cardiac clinical trials, nor of it going to market in Japan earlier.
The analysts however have clearly valued these things. along with the JV with Teva and many other factors.
You refuse to agree that MSB is an emerging blue chip, but you act as if it already should be one.
Great madamswer, ....and in the process of discussion, it's easy...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
0.010(1.10%) |
Mkt cap ! $1.044B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 90.5¢ | $4.638M | 5.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 152669 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 51069 | 3 |
View Market Depth
| Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |